Welcome to our dedicated page for Annexon news (Ticker: ANNX), a resource for investors and traders seeking the latest updates and insights on Annexon stock.
Annexon develops targeted immunotherapies for neuroinflammatory and classical complement-mediated diseases, with programs built around C1q and the classical complement pathway. Company news centers on clinical and regulatory progress for vonaprument in geographic atrophy, tanruprubart in Guillain-Barré syndrome, and ANX1502 as an oral C1 inhibitor for autoimmune disease.
Recurring updates also include quarterly financial results, research and development spending, cash runway disclosures, investor conference presentations, key opinion leader events, and equity inducement grants under Nasdaq rules. The company’s announcements connect pipeline progress with its balance sheet and public-company governance activity.
Annexon, Inc. (Nasdaq: ANNX) announced the closing of its initial public offering of 14,750,000 shares of common stock at $17.00 per share, generating approximately $250.8 million in gross proceeds. The stock began trading on July 24, 2020, with a 30-day option for underwriters to purchase an additional 2,212,500 shares. J.P. Morgan, BofA Securities, and Cowen are the joint book-running managers. This follows the effective registration of the offering on July 23, 2020. Annexon focuses on therapies for classical complement-mediated disorders, with an emphasis on autoimmune and neurodegenerative diseases.